Literature DB >> 9303183

Cellular uptake properties of a 2'-amino/2'-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA.

P L Fell1, A J Hudson, M A Reynolds, N Usman, S Akhtar.   

Abstract

Catalytic RNA or ribozymes have important potential applications as molecular biological tools in the study of gene expression and as therapeutic inhibitors of disease-causing genes. Very little is known, however, about the cellular uptake mechanisms of exogenously delivered synthetic ribozymes. In this study, we have characterized the uptake properties of a synthetic, 2'-O-methyl-modified ribozyme containing U4/U7 amino groups within the catalytic core of the hammerhead motif. The cellular uptake of the internally [32P]-radiolabeled hammerhead ribozyme in U87-MG glioma cells was temperature, energy, and pH dependent and involved an active process that could be competed with cold ribozyme of the same chemistry and sequence, an all 2'-O-methyl-modified ribozyme of the same sequence, antisense PS-ODNs, and a variety of other polyanions (salmon sperm DNA, spermidine, dextran sulfate, and heparin). Subcellular distribution studies of fluorescently labeled ribozymes confirmed an extranuclear, punctate localization similar to that observed for an endosomal marker, dextran. Our study highlights that hammerhead ribozymes, despite exhibiting a defined secondary structure, enter cells by an endocytic mechanism that appears to be similar to that reported for a variety of antisense ODNs. These observations should facilitate the development of more efficient delivery systems.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303183     DOI: 10.1089/oli.1.1997.7.319

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  7 in total

1.  Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.

Authors:  B Bramlage; S Alefelder; P Marschall; F Eckstein
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

2.  Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: evidence for non-conventional intracellular trafficking.

Authors:  Philippe de Diesbach; Francisca N'Kuli; Catherine Berens; Etienne Sonveaux; Michel Monsigny; Annie-Claude Roche; Pierre J Courtoy
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

3.  New modalities in oncology: ribozymes.

Authors:  C Casey Cunningham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-07

Review 4.  Complexity in interpretation of embryonic epithelial-mesenchymal transition in response to transforming growth factor-beta signaling.

Authors:  Shaheen Ahmed; Ali Nawshad
Journal:  Cells Tissues Organs       Date:  2007       Impact factor: 2.481

Review 5.  Angiozyme: a novel angiogenesis inhibitor.

Authors:  D E Weng; N Usman
Journal:  Curr Oncol Rep       Date:  2001-03       Impact factor: 5.075

6.  Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor.

Authors:  Andrew J Hollins; Mustapha Benboubetra; Yadollah Omidi; Bernd H Zinselmeyer; Andreas G Schatzlein; Ijeoma F Uchegbu; Saghir Akhtar
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

7.  Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I.

Authors:  Tatiana A Slastnikova; Eftychia Koumarianou; Andrey A Rosenkranz; Ganesan Vaidyanathan; Tatiana N Lupanova; Alexander S Sobolev; Michael R Zalutsky
Journal:  EJNMMI Res       Date:  2012-10-29       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.